Finland· FI-REL-REL59277
Eladynos
A abaloparatide product containing abaloparatide, registered in Finland by Theramex Ireland Limited. The same ATC class is registered in 12 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Abaloparatide is registered in 12 of 19 countries.
Countries holding a registration under ATC H05AA04 (abaloparatide), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 8 of them publish a price we can compare per daily dose
Abaloparatide · ATC H05AA04
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Abaloparatide
- Manufacturer
- Theramex Ireland Limited
- Country
- Finland (FI)
- ATC code
- H05AA04
- ATC class
- Abaloparatide
- Defined daily dose
- 80 mcg, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
2 interactions on record for abaloparatide.
Graded by severity as the source publishes them — 2 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Abaloparatide · interactions on record
2 records
- 2 moderate
Most severe, free to view
- CalcipotriolD05AX02moderate
- CalcitriolD05AX03moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Abaloparatide in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaELADYNOSTheramex Ireland Limited, Dublin
- United StatesTymlosRadius Health, Inc.
- SpainELADYNOS 80 MICROGRAMOS/DOSIS SOLUCION INYECTABLE EN PLUMA PRECARGADATheramex Ireland Limited
- United KingdomEladynos 80micrograms/40microlitres solution for injection 1.5ml pre-filled pensTheramex HQ UK Ltd
- IrelandEladynos 80 micrograms/dose solution for injection in pre-filled penTheramex Ireland Limited
- BelgiumEladynos 80 µg/doseTheramex Ireland
- ItalyELADYNOS*1 penna 1,5 ml 2 mg/mlTHERAMEX IRELAND LIMITED
- NetherlandsEladynos 80 microgram/dosis oplossing voor injectie in een voorgevulde penTheramex Ireland Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Eladynos
- Liechtenstein · Eladynos
- Norway · Eladynos
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/66c8cdef-c0b0-4356-8b43-2ea627ca1eb0 GET /v1/drugs/66c8cdef-c0b0-4356-8b43-2ea627ca1eb0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "injektioneste, liuos, esitäytetty kynä",
"route": "Ihon alle",
"ddd_unit": null,
"strength": "80 mikrog/annos",
"atc_label": "abaloparatidi",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/22/1706/001-002",
"fimea_rel_id": "REL59277",
"authorised_at": "2022-12-12"
}See everything about abaloparatide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.